Levothyroxine and sevelamer: listen to the patient.
Antonio
A
Granata
Fulvio
F
Floccari
Maurizio
M
Gallieni
D015746:Abdominal Pain / Q000209:etiology; D002614:Chelating Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003248:Constipation / Q000139:chemically induced / Q000503:physiopathology; D004334:Drug Administration Schedule; D004347:Drug Interactions; D020249:Hormone Replacement Therapy; D006801:Humans; D054559:Hyperphosphatemia / Q000517:prevention & control; D007408:Intestinal Absorption / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D016226:Phosphorus, Dietary / Q000037:antagonists & inhibitors; D011073:Polyamines / Q000009:adverse effects* / Q000627:therapeutic use; D006435:Renal Dialysis; D051436:Renal Insufficiency, Chronic / Q000150:complications / Q000188:drug therapy / Q000628:therapy; D000069603:Sevelamer; D013965:Thyroidectomy / Q000009:adverse effects; D013974:Thyroxine / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D016896:Treatment Outcome
D002614:Chelating Agents; D016226:Phosphorus, Dietary; D011073:Polyamines; D000069603:Sevelamer; D013974:Thyroxine